No Carolina / NY / Florida
Ph: 561.316.3330

NSF TraQtion Powers Novozymes’ Raw Material Management in Industry First

Novozymes has successfully implemented NSF TraQtion for managing raw material quality and continuously improve compliance for the production of enzymes and proteins across several industries

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • NSF, a leading global public health and safety organization, is pleased to announce that Novozymes, a leader in biosolutions, has become the world's first company to implement NSF TraQtion software for managing the quality and compliance of raw materials used in the production of enzymes and proteins serving multiple industries.
  • By harnessing advanced technologies and industry expertise, NSF TraQtion empowers organizations to proactively manage risk, ensure compliance and product quality, and fortify the overall resilience of their supply chains in a single, secure platform,” stated David Lonza, Vice President, Health Sciences, NSF.
  • NSF TraQtion is a cloud-based quality and compliance software that provides organizations with a comprehensive platform to proactively manage their supply chain, sites, and product quality.

NSF, a leading global public health and safety organization, is pleased to announce that Novozymes, a leader in biosolutions, has become the world’s first company to implement NSF TraQtion software for managing the quality and compliance of raw materials used in the production of enzymes and proteins serving multiple industries.

NSF TraQtion is a cloud-based quality and compliance software that provides organizations with a comprehensive platform to proactively manage their supply chain, sites, and product quality. NSF TraQtion was initially developed to help customers maintain a higher level of food safety and quality compliance. Its implementation by Novozymes demonstrates the versatility of the software across diverse industries, offering timely and insightful information for making informed decisions.

As an industry pioneer in risk management and mitigation solutions, NSF has a proven track record of ensuring product safety, quality, and compliance across various sectors, including food and health science. In today’s increasingly complex supply chains, risks stemming from globalization, extreme weather events, geopolitical influences, and persistent raw material inflation highlight the need for more robust supply chain management solutions.

Matthew Allen, Senior Director, Food & Sustainability Advisory Solutions at NSF……

“We are delighted to have Novozymes as a client utilizing NSF TraQtion. This achievement showcases the versatility and effectiveness of NSF TraQtion digital solutions across diverse industries. With our extensive expertise and deep understanding of global supply chain dynamics, we are confident in our ability to support Novozymes in enhancing their raw material management process.”

Novozymes is also exploring applications of NSF TraQtion within dietary supplements and health sciences in the future, marking the start of NSF TraQtion’s expansion into these sectors.

NSF TraQtion software offers comprehensive data management and business intelligence capabilities. It combines decades of industry expertise with real-time digital insights in a trusted, cloud-based solution that provides businesses with the assurance they need to confidently manage complex and critical data – including supplier compliance, regulatory requirements, and environmental reporting.

“The adoption of NSF TraQtion by Novozymes underscores NSF’s commitment to delivering cutting-edge solutions to address emerging challenges across industries. By harnessing advanced technologies and industry expertise, NSF TraQtion empowers organizations to proactively manage risk, ensure compliance and product quality, and fortify the overall resilience of their supply chains in a single, secure platform,” stated David Lonza, Vice President, Health Sciences, NSF.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

By using this website you agree to accept Medical Device News Magazine Privacy Policy